Management of hepatitis C virus infection: the basics

Area of Science:

• Hepatology
• Virology
• Pharmacogenomics

Background:

• Chronic hepatitis C virus (HCV) infection affects 170 million worldwide, with many unaware of their status.
• HCV genotype 1 is most common in the US and less responsive to interferon alfa-based therapy.
• Direct-acting antiviral (DAA) drugs improve treatment outcomes but require combination therapy to prevent resistance.

Purpose of the Study:

• To review the basics of current hepatitis C virus (HCV) treatments.
• To discuss the role of direct-acting antiviral (DAA) drugs in managing HCV genotype 1.
• To highlight predictors of treatment response, including IL28B genotype.

Main Methods:

• Review of current direct-acting antiviral (DAA) therapies for HCV.
• Discussion of combination therapy regimens including peginterferon alfa and ribavirin.
• Consideration of pharmacogenetic factors like IL28B genotype in treatment response.

Main Results:

• DAA drugs significantly increase sustained virologic response (SVR) rates in genotype 1 HCV.
• Combination therapy with DAAs, peginterferon alfa, and ribavirin is necessary to prevent resistance.
• Pharmacogenetic IL28B genotype influences treatment response.
• Stopping/futility rules allow for earlier treatment decisions in triple-drug therapy.

Conclusions:

• Sustained virologic response (SVR) is the primary goal of HCV treatment, reducing long-term complications.
• DAA-based triple therapy offers improved outcomes for HCV genotype 1 infection.
• Understanding treatment predictors, including IL28B genotype, is crucial for effective HCV management.